Medicament Comprising Donepezil and Carbostyril Derivative for Alzheimer Treatment
DOI:
https://doi.org/10.61841/9qb90e93Keywords:
Acetylcholinesterase, Alzheimer’s, Carbostyril, Donepezil, Dementia, Pharmacological, VascularAbstract
Donepezil is the predominant Alzheimer's drug in over fifty countries. The Donepezil is a strongly active and reversible piperidine derivative with AChEI activity that has the largest pharmacological benefit for cognitive recovery and reaction risk (40% –58%), side effects (6.0 % –13.0 %) and side effects (5.0% –13.0%) in comparison to AD compared with traditional acetylcholinesterase inhibitors (AChEI). Although donepezil is an inexpensive treatment, most research indicate that this drug can provide mild to extreme DA with a mild, slower development of disease and a reduced institutionalization of attitude, cognition and daily life. This is a modest advantage. Donepezil will also be helpful for people with vascular dementia in the same manner as AD. This paper aims at presenting a medication that includes donepezil and carbostyril derivatives, or even salt, to cure Alzheimer's with impressive synergistic methods to combat the disease of Alzheimer.
Downloads
References
[1] Q. Zhang and C. Zhang, “Alzheimer,” in Nanotechnology Methods for Neurological Diseases and Brain Tumors: Drug Delivery across the Blood-Brain Barrier, 2017.
[2] J. M. Long and D. M. Holtzman, “Alzheimer Disease: An Update on Pathobiology and Treatment Strategies,” Cell. 2019.
[3] C. Van Cauwenberghe, C. Van Broeckhoven, and K. Sleegers, “The genetic landscape of Alzheimer disease: Clinical implications and perspectives,” Genetics in Medicine. 2016.
[4] A. W. Laxton and A. M. Lozano, “Deep brain stimulation for the treatment of alzheimer disease and dementias,” World Neurosurgery. 2013.
[5] S. Jevtic, A. S. Sengar, M. W. Salter, and J. A. McLaurin, “The role of the immune system in Alzheimer
disease: Etiology and treatment,” Ageing Research Reviews. 2017.
[6] Alzheimer’s & Dementia, “Basics of Alzheimer ’ S Disease,” Alzheimer’s Assoc. Rep., 2015.
[7] Y. Shi et al., “ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy,”
Nature, 2017.
[8] M. E. Peters et al., “Citalopram for the Treatment of Agitation in Alzheimer Dementia,” J. Geriatr. Psychiatry Neurol., 2016.
[9] J. Folch et al., “Review of the advances in treatment for Alzheimer disease: strategies for combating β-amyloid protein,” Neurol. (English Ed., 2018.
[10] C. B. Pocernich and D. A. Butterfield, “Elevation of glutathione as a therapeutic strategy in Alzheimer disease,” Biochimica et Biophysica Acta - Molecular Basis of Disease. 2012.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
